Risk of acute leukemia and myelodysplastic syndromes in patients with monoclonal gammopathy of undetermined significance (MGUS): A population-based study of 17 315 patients

Leukemia

Volumn 27, Issue 6, 2013, Pages 1391-1393

  Roeker, L E ^a   Larson, D R ^b   Kyle, R A ^c   Kumar, S ^c   Dispenzieri, A ^c   Rajkumar, S V ^c  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^b Division of Biostatistics   (United States)

^c MAYO CLINIC   (United States)

Author keywords

acute leukemias; MGUS; monoclonal gammopathy of undetermined significance; myelodysplastic syndromes; population based screening

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M;

ACUTE LEUKEMIA; ADULT; AGED; ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HAZARD RATIO; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; MYELODYSPLASTIC SYNDROME; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL;

ADULT; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; MYELODYSPLASTIC SYNDROMES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RISK FACTORS;

EID: 84878909164     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.34     Document Type: Article

References (16)

1. Kyle RA, Pierre RV, Bayrd ED. Multiple myeloma and acute myelomonocytic leukemia. N Engl J Med 1970; 283: 1121-1125.
2. Cuzick J, Erskine S, Edelman D, Galton DA. A comparison of the incidence of the myelodysplastic syndrome and acute myeloid leukaemia following melphalan and cyclophosphamide treatment for myelomatosis. A report to the Medical Research Council's working party on leukaemia in adults. Br J Cancer 1987; 55: 523-529. (Pubitemid 17098861)
3. Bergsagel DE, Bailey AJ, Langley GR, MacDonald RN, White DF, Miller AB. The chemotherapy on plasma-cell myeloma and the incidence of acute leukemia. N Engl J Med 1979; 301: 743-748. (Pubitemid 10250478)
4. Govindarajan R, Jagannath S, Flick JT, Vesole DH, Sawyer J, Barlogie B et al. Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma. Br J Haematol 1996; 95: 349-353. (Pubitemid 26360224)
5. Yang J, Terebelo HR, Zonder JA. Secondary primary malignancies in multiple myeloma: an old nemesis revisited. Adv Hematol 2012; 2012: 801495.
6. McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 2012; 366: 1770-1781.
7. Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 2012; 366: 1782-1791.
8. Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci MT, Catalano J et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med 2012; 366: 1759-1769.
9. Thomas A, Mailankody S, Korde N, Kristinsson SY, Turesson I, Landgren O. Second malignancies after multiple myeloma: from 1960 s-2010 s. Blood 2012; 119: 2731-2737.
10. Travis LB, Rabkin CS, Brown LM, Allan JM, Alter BP, Ambrosone CB et al. Cancer survivorship-genetic susceptibility and second primary cancers: research strategies and recommendations. J Natl Cancer Inst 2006; 98: 15-25. (Pubitemid 43057089)
11. Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006; 354: 1362-1369.
12. Kyle RA. Monoclonal gammopathy of undetermined significance. Natural history in 241 cases. Am J Med 1978; 64: 814-826. (Pubitemid 8328130)
13. Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002; 346: 564-569. (Pubitemid 34438817)
14. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003; 121: 749-757.
15. Bida JP, Kyle RA, Therneau TM, Melton 3rd LJ, Plevak MF, Larson DR et al. Disease associations with monoclonal gammopathy of undetermined significance: a population-based study of 17,398 patients. Mayo Clinic Proceedings 2009; 84: 685-693.
16. Mailankody S, Pfeiffer RM, Kristinsson SY, Korde N, Bjorkholm M, Goldin LR et al. Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS). Blood 2011; 118: 4086-4092.